Enovis (ENOV) Insider Oliver Engert Buys $21K of Stock

Enovis Corporation's Chief Administrative Officer, Oliver Engert, has made another move in the market by purchasing additional shares of the company. On June 15, 2026, Engert bought 1,000 shares of Enovis Corporation (NYSE: ENOV) at an average price of $20.92, amounting to a total value of $20,920. This purchase was not part of a pre-planned trading program.

Insider Buying and Selling at Enovis Corporation

Oliver Engert has been active in acquiring Enovis shares recently. Prior to the June 15 purchase, Engert bought 1,000 shares at $20.99 and 1,200 shares at $21.62 on June 11, and 1,000 shares at $23.00 on June 10. Earlier in the month, he also purchased 1,000 shares at $22.22 on June 1. These transactions indicate a consistent increase in his stake in the company.

Other Institutional Activity in Enovis Corporation

Several institutional investors have also adjusted their positions in Enovis. BlackRock, Inc. increased its holdings by 1,029,845 shares, resulting in a total of 9,936,469 shares valued at approximately $226.05 million. On the other hand, American Century Companies Inc reduced its stake by 490,394 shares, leaving it with 4,768,921 shares worth about $108.49 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both made notable additions, with the former now holding 3,808,629 shares valued at $86.65 million, and the latter at 2,552,351 shares worth $58.07 million. Dimensional Fund Advisors LP trimmed its position by 236,014 shares, ending with 2,545,922 shares valued at $57.92 million.

Enovis Corporation Stock Up 11.5%

Shares of Enovis Corporation (NYSE: ENOV) are currently trading at around $20.98. The company has a market capitalization of approximately $1.24 billion. Enovis's forward P/E ratio stands at 5.31, reflecting expectations of future earnings. The stock's beta is 1.493, indicating higher volatility compared to the broader market. Over the past 52 weeks, the stock has traded between $20.55 and $36.82, with a 50-day moving average of $23.98 and a 200-day moving average of $26.46. The company's current ratio is 2.037, and its quick ratio is 0.784, with a debt-to-equity ratio of 95.34.

Recent Earnings

Enovis Corporation reported revenue of approximately $2.28 billion, with a modest growth rate of 5.4%. However, the company is currently not profitable, as indicated by a net margin of -49.92% and a return on equity of -55.35%. The company is expected to announce its next earnings on August 6, 2026.

Analysts Set New Price Targets

Analysts have been optimistic about Enovis's prospects. BTIG reiterated its buy rating with a target price of $39 on May 22, 2026. Evercore ISI Group and Wells Fargo both maintained their buy ratings, setting target prices of $36 and $40, respectively, on May 8, 2026. The consensus among 11 analysts is a strong buy, with a mean target price of $43.00.

About Enovis Corporation

Enovis Corporation is a healthcare company based in Wilmington, Delaware. It specializes in medical devices and provides solutions for orthopedic and reconstructive surgery. The company operates in two main segments: Prevention and Recovery, and Reconstructive. Enovis develops products like orthopedic braces, therapy systems, and surgical implants used in joint replacement and limb reconstruction. Led by CEO Damien McDonald, Enovis employs around 7,802 people and distributes its products globally through a network of distributors and direct sales.

Bottom Line

Oliver Engert's recent share purchases suggest confidence in Enovis Corporation's future. With a market cap of $1.24 billion and a strong buy consensus from analysts, Enovis is a company to watch. However, it's essential to remember that insider trading reports are backward-looking and may not reflect current positions or intentions.